塔拉妥单抗在经治小细胞肺癌中持续临床获益及颅内活性:DeLLphi-300 试验更新
DeLLphi-300 I 期试验扩展随访(中位随访 12.1 个月)纳入 152 例经治小细胞肺癌患者,接受塔拉妥单抗 ≥10 mg 每两周、每三周或每 21 天周期第 1 天和第 8 天给药。总客观缓解率 25.0%,中位缓解持续时间 11.2 个月(95%CI 6.6 至 22.3),中位总生存期 17.5 个月(95%CI 11.4 至不可估计)。
要点
- 经治小细胞肺癌总客观缓解率 25.0%,中位缓解持续时间 11.2 个月。
- 10 mg 每两周组 17 例,客观缓解率 35.3%,中位总生存期 20.3 个月。
- 基线中枢神经系统病灶 ≥10 mm 者中 62.5%(10/16)出现 ≥30% 的肿瘤缩小。
核心结论
- 在 DeLLphi-300 扩展随访中,塔拉妥单抗在经治小细胞肺癌中显示出前所未有的生存获益和潜在的颅内活性。
研究设计与样本
- DeLLphi-300 I 期试验扩展随访,纳入完全入组、接受塔拉妥单抗 ≥10 mg 每两周、每三周或每 21 天周期第 1 天和第 8 天给药的患者 152 例,中位随访 12.1 个月(范围 0.2-34.3)。
主要发现
- 总体客观缓解率为 25.0%,中位缓解持续时间为 11.2 个月(95%CI 6.6 至 22.3),中位总生存期为 17.5 个月(95%CI 11.4 至不可估计)。
- 接受 10 mg 每两周治疗的 17 例患者中,客观缓解率为 35.3%,中位缓解持续时间为 14.9 个月(95%CI 3.0 至不可估计),中位总生存期为 20.3 个月(95%CI 5.1 至不可估计),29.4% 的患者治疗时间 ≥52 周且疾病控制持续。
- 未发现新的安全性信号。
- 在改良神经肿瘤脑转移疗效评估分析中,基线中枢神经系统病灶 ≥10 mm 的患者中 62.5%(10/16)观察到中枢神经系统肿瘤缩小 ≥30%,包括部分既往脑放疗后很久才出现肿瘤缩小的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, has shown durable anticancer activity and manageable safety in previously treated small cell lung cancer (SCLC) in DeLLphi-300 phase I and DeLLphi-301 phase II trials. Here, we report extended follow-up of DeLLphi-300 (median follow-up, 12.1 months [range, 0.2-34.3]) in fully enrolled cohorts treated with tarlatamab ≥10 mg dose administered once every two weeks, once every three weeks, or once on day 1 and once on day 8 of a 21-day cycle (N = 152). Overall, the objective response rate (ORR) was 25.0%; the median duration of response (mDOR) was 11.2 months (95% CI, 6.6 to 22.3), and the median overall survival (mOS) was 17.5 months (95% CI, 11.4 to not estimable [NE]). Among 17 patients receiving 10 mg tarlatamab once every two weeks, the ORR was 35.3%, the mDOR was 14.9 months (95% CI, 3.0 to NE), the mOS was 20.3 months (95% CI, 5.1 to NE), and 29.4% had sustained disease control with time on treatment ≥52 weeks. No new safety signals were identified. In modified Response Assessment in Neuro-Oncology Brain Metastases analyses, CNS tumor shrinkage of ≥30% was observed in 62.5% of patients (10 of 16) who had a baseline CNS lesion of ≥10 mm, including in a subset of patients with tumor shrinkage long after previous brain radiotherapy. In DeLLphi-300 extended follow-up, tarlatamab demonstrated unprecedented survival and potential findings of intracranial activity in previously treated SCLC.
引用
- Dowlati A, Hummel HD, Champiat S, et al. Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. J Clin Oncol. 2024. PMID: 39208379. doi:10.1200/JCO.24.00553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。